Encouraging and Enabling a Science-Based Approach to Ecological Restoration

Botanic gardens harbour many of the skills necessary for undertaking ecological restoration. This includes strong horticultural and taxonomic expertise, seed collection, conservation and propagation skills, the ability to design and lead monitoring programmes, as well as providing training and outreach to the public. This unique set of skills is rarely found within other institutions. Many of the world’s botanic gardens share a common mission: to secure plant diversity, working within the framework of national and international policies. Botanic gardens are therefore not only well-placed to lead ecological restoration initiatives, but it is their goal and responsibility to apply their knowledge, expertise and skills to addressing ecological degradation. In recognition of this, the Ecological Restoration Alliance of Botanic Gardens (ERA) was formed in 2011, a consortium of botanic gardens applying their skills to lead successful ecological restoration initiatives in diverse habitat and cultural contexts across six continents. The ERA is coordinated by Botanic Gardens Conservation International (BGCI). This article summarises ERA progress to date, and provides a case study from Kenya, which demonstrates botanic gardens’ ability to undertake ecological restoration and highlights the value of the ERA

A microfluidic atmospheric-pressure plasma reactor for water treatment

A dielectric barrier discharge microfluidic plasma reactor, operated at atmospheric pressure, was studied for its potential to treat organic contaminants in water. Microfluidic technology represents a compelling approach for plasma-based water treatment due to inherent characteristics such as a large surface-area-to-volume ratio and flow control, in inexpensive and portable devices. The microfluidic device in this work incorporated a dielectric barrier discharge generated in a continuous gas flow stream of a two-phase annular flow regime in the microchannels of the device. Methylene blue in solution was used to investigate plasma induced degradation of dissolved organic compounds within the microfluidic device. The relative degradation rates of methylene blue were influenced by the residence time of the sample solution in the discharge zone, type of gas applied, channel depth and flow rate. Increasing the residence time inside the plasma region led to higher levels of degradation. Oxygen was found to be the most effective gas, with the spectra obtained using Liquid Chromatography-Mass Spectroscopy indicating the most significant degradation. By reducing the channel depth from 100 to 50 µm, the best results were obtained, achieving a greater than 97% level of methylene blue degradation. The microfluidic system presented here demonstrates proof-of-concept that plasma technology can be utilised as an advanced oxidation process for water treatment, with the potential to eliminate water treatment consumables such as filters and disinfectants

The effectiveness and cost-effectiveness of of community diagnostic centres: a rapid review

Objectives: To examine the effectiveness of community diagnostic centres as a potential solution to increasing capacity and reducing pressure on secondary care in the UK.Methods: A comprehensive search for relevant primary studies was conducted in a range of electronic sources in August 2022. Screening and critical appraisal were undertaken by two independent reviewers. There were no geographical restrictions or limits to year of publication. A narrative synthesis approach was used to analyse data and present findings.Results: Twenty primary studies evaluating twelve individual diagnostic centres were included. Most studies were specific to cancer diagnosis and evaluated diagnostic centres located within hospitals. The evidence of effectiveness appeared mixed. There is evidence to suggest diagnostic centres can reduce various waiting times and reduce pressure on secondary care. However, cost-effectiveness may depend on whether the diagnostic centre is running at full capacity. Most included studies used weak methodologies that may be inadequate to infer effectiveness.Conclusion: Further well-designed, quality research is needed to better understand the effectiveness and cost-effectiveness of community diagnostic centres

Comparable reductions in hyperpnoea-induced bronchoconstriction and markers of airway inflammation after supplementation with 6·2 and 3·1 g/d of long-chain n-3 PUFA in adults with asthma

Although high dose n-3 PUFA supplementation reduces exercise- and hyperpnoea-induced bronchoconstriction (EIB/HIB), there are concurrent issues with cost, compliance and gastrointestinal discomfort. It is thus pertinent to establish the efficacy of lower n-3 PUFA doses. Eight male adults with asthma and HIB and eight controls without asthma were randomly supplemented with two n-3 PUFA doses (6·2 g/d (3·7 g EPA and 2·5 g DHA) and 3·1 g/d (1·8 g EPA and 1·3 g DHA)) and a placebo, each for 21 d followed by 14 d washout. A eucapnic voluntary hyperpnoea (EVH) challenge was performed before and after treatments. Outcome measures remained unchanged in the control group. In the HIB group, the peak fall in forced expiratory volume in 1 s (FEV1) after EVH at day 0 (−1005 (sd 520) ml, −30 (sd 18) %) was unchanged after placebo. The peak fall in FEV1 was similarly reduced from day 0 to day 21 of 6·2 g/d n-3 PUFA (−1000 (sd 460) ml, −29 (sd 17) % v. −690 (sd 460) ml, −20 (sd 15) %) and 3·1 g/d n-3 PUFA (−970 (sd 480) ml, −28 (sd 18) % v. −700 (sd 420) ml, −21 (sd 15) %) (P<0·001). Baseline fraction of exhaled nitric oxide was reduced by 24 % (P=0·020) and 31 % (P=0·018) after 6·2 and 3·1 g/d n-3 PUFA, respectively. Peak increases in 9α, 11β PGF2 after EVH were reduced by 65 % (P=0·009) and 56 % (P=0·041) after 6·2 and 3·1 g/d n-3 PUFA, respectively. In conclusion, 3·1 g/d n-3 PUFA supplementation attenuated HIB and markers of airway inflammation to a similar extent as a higher dose. Lower doses of n-3 PUFA thus represent a potentially beneficial adjunct treatment for adults with asthma and EIB

A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation

Gut microbes have a substantial influence on systemic immune function and allergic sensitisation. Manipulation of the gut microbiome through prebiotics may provide a potential strategy to influence the immunopathology of asthma. This study investigated the effects of prebiotic Bimuno-galactooligosaccharide (B-GOS) supplementation on hyperpnoea-induced bronchoconstriction (HIB), a surrogate for exercise-induced bronchoconstriction, and airway inflammation. A total of ten adults with asthma and HIB and eight controls without asthma were randomised to receive 5·5 g/d of either B-GOS or placebo for 3 weeks separated by a 2-week washout period. The peak fall in forced expiratory volume in 1 s (FEV1) following eucapnic voluntary hyperpnoea (EVH) defined HIB severity. Markers of airway inflammation were measured at baseline and after EVH. Pulmonary function remained unchanged in the control group. In the HIB group, the peak post-EVH fall in FEV1 at day 0 (−880 (SD 480) ml) was unchanged after placebo, but was attenuated by 40 % (−940 (SD 460) v. −570 (SD 310) ml, P= 0·004) after B-GOS. In the HIB group, B-GOS reduced baseline chemokine CC ligand 17 (399 (SD 140) v. 323 (SD 144) pg/ml, P =0·005) and TNF-α (2·68 (SD 0·98) v. 2·18 (SD 0·59) pg/ml, P= 0·040) and abolished the EVH-induced 29 % increase in TNF-α. Baseline C-reactive protein was reduced following B-GOS in HIB (2·46 (SD 1·14) v. 1·44 (SD 0·41) mg/l, P=0·015) and control (2·16 (SD 1·02) v. 1·47 (SD 0·33) mg/l, P=0·050) groups. Chemokine CC ligand 11 and fraction of exhaled nitric oxide remained unchanged. B-GOS supplementation attenuated airway hyper-responsiveness with concomitant reductions in markers of airway inflammation associated with HIB

Evaluation of a microfluidic atmospheric-pressure plasma reactor for water treatment

A dielectric barrier discharge (DBD) microfluidic plasma reactor, operated at atmospheric pressure, was studied for its potential to treat organic contaminants in water. The proposed microfluidic plasma reactor (MPR) allows in situ production of plasma in a continuous flow, operated under atmospheric pressure, for plasma-based water treatment. The MPR operates with glass as the dielectric barrier, where plasma is generated in the continuous gas flow stream of a gas-liquid two-phase annular flow regime in the microchannels. The microchannels have dimensions of 100 µm depth, 250 µm width and the plasma is generated in an approximately 21 cm length of microchannel arranged in a serpentine pattern. Methylene blue (MB) in solution was used as a model organic to investigate its degradation by plasma generated in the microchannels. The influence of discharge time, residence time and gas sources, i.e. air, argon and oxygen, on MB degradation was studied. The percentage degradation increased with lower liquid flow rates, with maximum degradation of MB achieved at a liquid flow rate of 35 µL/min and inlet gas pressure of 1 bar using oxygen as the working gas. Liquid chromatography/mass spectrometry analysis of the MB solution after treatment suggests degradation through fragmentation of MB. It is intended that the device will be used as proof of concept to introduce plasma technology as an advanced oxidation process for water treatment, with the potential to achieve total mineralization of dissolved organic materials and microbial inactivation, replacing water treatment chemicals and consumables

Measuring the effect of wing tears on flight in common pipistrelle bats (Pipistrellus pipistrellus)

Bat wings are susceptible to tearing. Many bats are admitted to care with wing tears and their flight is subjectively measured prior to release. This study presents a new method to objectively measure the effect of bat wing tears on the flight of common pipistrelle bats, Pipistrellus pipistrellus. Bats were filmed and their wing movements and body positions tracked using freely available software. Results found that bats with bilateral tears moved their wings with smaller movements, and with more wing beats per second. Bats with wing tears tended to tilt their whole body towards the healthier wing - which is the wing with no or smaller wing tears. Differences in wing movements and body positioning suggest that flight might be affected in bats with wing tears, and future work should assess whether foraging and survival are also affected in these animals

Choice of Moisturiser for Eczema Treatment (COMET):feasibility study of a randomised controlled parallel group trial in children recruited from primary care

OBJECTIVES: To determine the feasibility of a randomised controlled trial of ‘leave on’ emollients for children with eczema. DESIGN: Single-centre, pragmatic, 4-arm, observer-blinded, parallel, randomised feasibility trial. SETTING: General practices in the UK. PARTICIPANTS: Children with eczema aged 1 month to <5 years. OUTCOME MEASURES: Primary outcome—proportion of parents who reported use of the allocated study emollient every day for the duration of follow-up (12 weeks). Other feasibility outcomes—participant recruitment and retention, data collection and completeness and blinding of observers to allocation. INTERVENTIONS: Aveeno lotion, Diprobase cream, Doublebase gel, Hydromol ointment. RESULTS: 197 children were recruited—107 by self-referral (mainly via practice mail-outs) and 90 by inconsultation (clinician consenting and randomising) pathways. Participants recruited inconsultation were younger, had more severe Patient-Oriented Eczema Measure scores and were more likely to withdraw than self-referrals. Parents of 20 (10%) of all the randomised participants reported using the allocated emollient daily for 84 days. The use of other non-study emollients was common. Completeness of data collected by parent-held daily diaries and at monthly study visits was good. Daily diaries were liked (81%) but mainly completed on paper rather than via electronic (‘app’) form. Major costs drivers were general practitioner consultations and eczema-related prescriptions. Observer unblinding was infrequent, and occurred at the baseline or first follow-up visit through accidental disclosure. CONCLUSIONS: It is feasible in a primary care setting to recruit and randomise young children with eczema to emollients, follow them up and collect relevant trial data, while keeping observers blinded to their allocation. However, reported use of emollients (study and others) has design implications for future trials. TRIAL REGISTRATION NUMBER: ISRCTN21828118/EudraCT2013-003001-26

Maternal and fetal cardiometabolic recovery following ultrasound-guided high-intensity focused ultrasound placental vascular occlusion.

High-intensity focused ultrasound (HIFU) is a non-invasive method of selective placental vascular occlusion, providing a potential therapy for conditions such as twin-twin transfusion syndrome. In order to translate this technique into human studies, evidence of prolonged fetal recovery and maintenance of a healthy fetal physiology following exposure to HIFU is essential. At 116 ± 2 days gestation, 12 pregnant ewes were assigned to control ( n = 6) or HIFU vascular occlusion ( n = 6) groups and anaesthetized. Placental blood vessels were identified using colour Doppler ultrasound; HIFU-mediated vascular occlusion was performed through intact maternal skin (1.66 MHz, 5 s duration, in situ ISPTA 1.8-3.9 kW cm-2). Unidentifiable colour Doppler signals in targeted vessels following HIFU exposure denoted successful occlusion. Ewes and fetuses were then surgically instrumented with vascular catheters and transonic flow probes and recovered from anaesthesia. A custom-made wireless data acquisition system, which records continuous maternal and fetal cardiovascular data, and daily blood sampling were used to assess wellbeing for 20 days, followed by post-mortem examination. Based on a comparison of pre- and post-treatment colour Doppler imaging, 100% (36/36) of placental vessels were occluded following HIFU, and occlusion persisted for 20 days. All fetuses survived. No differences in maternal or fetal blood pressure, heart rate, heart rate variability, metabolic status or oxygenation were observed between treatment groups. There was evidence of normal fetal maturation and no evidence of chronic fetal stress. There were no maternal injuries and no placental vascular haemorrhage. There was both a uterine and fetal burn, which did not result in any obstetric or fetal complications. This study demonstrates normal long-term recovery of fetal sheep from exposure to HIFU-mediated placental vascular occlusion and underlines the potential of HIFU as a potential non-invasive therapy in human pregnancy

Parents and GPs’ understandings and beliefs about food allergy testing in children with eczema:qualitative interview study within the Trial of Eczema allergy Screening Tests (TEST) feasibility trial

Aim To explore parent and general practitioner (GP) understanding and beliefs about food allergy testing for children with eczema.Design and setting Qualitative interview study in UK primary care within the Trial of Eczema allergy Screening Tests feasibility trial.Participants Semi-structured interviews with parents of children with eczema taking part in the feasibility study and GPs at practices hosting the study.Results 21 parents and 11 GPs were interviewed. Parents discussed a range of potential causes for eczema, including a role for food allergy. They believed allergy testing to be beneficial as it could potentially identify a cure or help reduce symptoms and they found negative tests reassuring, suggesting to them that no dietary changes were needed. GPs reported limited experience and uncertainty regarding food allergy in children with eczema. While some GPs believed referral for allergy testing could be appropriate, most were unclear about its utility. They thought it should be reserved for children with severe eczema or complex problems but wanted more information to advise parents and help guide decision making.Conclusions Parents’ motivations for allergy testing are driven by the desire to improve their child’s condition and exclude food allergy as a possible cause of symptoms. GPs are uncertain about the role of allergy testing and want more information about its usefulness to support parents and help inform decision making.Trial registration number ISRCTN15397185